INCB 50465-801: A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Parsaclisib (INCB050465)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501687-18-00

Acronym

INCB 50465-801

Enrollment

Registered

2023-01-31

Start date

2020-10-28

Completion date

Unknown

Last updated

2025-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced malignancies and IAI diseases

Brief summary

To assess AEs and SAEs reported in participants receiving parsaclisib as monotherapy or in combination with itacitinib, ruxolitinib, ibrutinib, or tafasitamab (including participants who remain on tafasitamab alone).

Interventions

DRUGJakavi 5 mg tablets

DRUGParsaclisib (INCB050465)

DRUGMINJUVI 200 mg powder for concentrate for solution for infusion

DRUGIMBRUVICA 140 mg hard capsules

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
To assess AEs and SAEs reported in participants receiving parsaclisib as monotherapy or in combination with itacitinib, ruxolitinib, ibrutinib, or tafasitamab (including participants who remain on tafasitamab alone).	—

Countries

Belgium, Czechia, Denmark, France, Italy, Poland, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026